Nanterinone (mesylate)

• UNSPSC Description:

  Nanterinone mesylate (UK-61260-27) is an orally active and positive inotropic and balanced-type vasodilating agent, partially based on phosphodiesterase III inhibition with venodilating properties. Nanterinone mesylate is promising for research of cardiovascular diseases[1].

• Target Antigen:

  Phosphodiesterase (PDE)

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/nanterinone-mesylate.html

• Smiles:

  O=C1NC2=C(C=C(N3C=C(C)N=C3C)C=C2C)C=C1.CS(=O)(O)=O

• Molecular Weight:

  349.40

• References & Citations:

  [1]Remme WJ, et al. Acute hemodynamic effects and preload-dependent cardiovascular profile of the partial phosphodiesterase inhibitor nanterinone in patients with mild to moderate heart failure. Cardiovasc Drugs Ther. 1996 May;10(2):137-44.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  102791-74-2